CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties

por Mayer, Lawrence D, Tardi, Paul, Louie, Arthur C
Publicado 2019

A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias

por Lin, Tara L., Newell, Laura F., Stuart, Robert K., Michaelis, Laura C., Rubenstein, Eric, Pentikis, Helen S., Callahan, Timothy, Alvarez, Donna, Liboiron, Barry D., Mayer, Lawrence D., Wang, Qi, Banerjee, Kamalika, Louie, Arthur C.
Publicado 2019

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemi...

por Lancet, Jeffrey E., Uy, Geoffrey L., Cortes, Jorge E., Newell, Laura F., Lin, Tara L., Ritchie, Ellen K., Stuart, Robert K., Strickland, Stephen A., Hogge, Donna, Solomon, Scott R., Stone, Richard M., Bixby, Dale L., Kolitz, Jonathan E., Schiller, Gary J., Wieduwilt, Matthew J., Ryan, Daniel H., Hoering, Antje, Banerjee, Kamalika, Chiarella, Michael, Louie, Arthur C., Medeiros, Bruno C.
Publicado 2018